AVAGE- tazarotene cream
Allergan, Inc.


AVAGE (tazarotene) Cream, 0.1% is indicated as an adjunctive agent for use in the mitigation (palliation) of facial fine wrinkling, facial mottled hyper- and hypopigmentation, and benign facial lentigines in patients who use comprehensive skin care and sunlight avoidance programs.

Limitations of Use:

  • AVAGE Cream does not eliminate or prevent wrinkles or restore more youthful skin.
  • AVAGE Cream does not reverse photoaging or repair sun damaged skin; AVAGE Cream does not mitigate coarse or deep wrinkling, tactile roughness, telangiectasia, skin laxity, keratinocytic atypia, melanocytic atypia, or dermal elastosis.
  • The safety and the effectiveness of AVAGE Cream for the prevention or treatment of actinic keratoses, skin neoplasms, or lentigo maligna have not been established.


2.1 Assessment Prior to Treatment Initiation

Obtain a pregnancy test within 2 weeks prior to AVAGE Cream therapy. Initiate AVAGE Cream therapy during a menstrual period [see Contraindications (4), Warnings and Precautions (5.1), and Use in Specific Populations (8.1, 8.3)].

Carefully assess facial pigmented lesions of concern by a qualified physician (e.g., dermatologist) before application of AVAGE Cream [see Warnings and Precautions (5.4)].

2.2 Important Administration Instructions

Avoid accidental transfer of AVAGE Cream into eyes, mouth, or other mucous membranes. If contact with mucous membranes occurs, rinse thoroughly with water [see Warnings and Precaution (5.2)].

Wash hands thoroughly after application.

Emollients or moisturizers can be applied either before or after applying AVAGE Cream. However, ensure that the first cream or lotion has absorbed into the skin and has dried completely before subsequent cream or lotion application. Use facial moisturizers as frequently as desired [see Warnings and Precaution (5.2)].

AVAGE Cream is for topical use only. AVAGE Cream is not for ophthalmic, oral, or intravaginal use.

Use effective sunscreens and wear protective clothing while using AVAGE Cream [see Warnings and Precaution (5.3)].

2.3 Dosage and Administration Instructions

Remove any makeup before applying AVAGE Cream to the face. Dry the skin before applying the cream after face washing, bathing, or showering.

Apply a pea-sized amount once a day at bedtime to lightly cover the entire face, including the eyelids, if desired.

Wash hands thoroughly after application.


Cream: 1 mg of tazarotene per gram (0.1%) of white cream in 30 gram tubes.


AVAGE Cream is contraindicated in :

  • Pregnancy. Retinoids may cause fetal harm when administered to a pregnant female [see Warnings and Precautions (5.1), Use in Specific Populations (8.1, 8.3)].
  • Individuals who have known hypersensitivity to any of its components [see Warnings and Precautions (5.2)].


5.1 Embryofetal Toxicity

Based on data from animal reproduction studies, retinoid pharmacology and the potential for systemic absorption, AVAGE Cream may cause fetal harm when administered to a pregnant female and is contraindicated during pregnancy. Safety in pregnant females has not been established. The potential risk to the fetus outweighs the potential benefit to the mother from AVAGE Cream use during pregnancy; therefore, discontinue AVAGE Cream as soon as pregnancy is recognized. Tazarotene elicits malformations and developmental effects associated with retinoids after topical and oral administration to pregnant rats and rabbits during organogenesis. However, limited case reports of pregnancy in females enrolled in clinical trials for AVAGE Cream have not reported a clear association with tazarotene and major birth defects or miscarriage risk [see Contraindications (4), Use in Specific Populations (8.1)].

Systemic exposure to tazarotenic acid is dependent upon the extent of the body surface area treated. In patients treated topically over sufficient body surface area, exposure could be in the same order of magnitude as in these orally treated animals. Although there may be less systemic exposure in the treatment of the face alone due to less surface area for application, tazarotene is a teratogenic substance in animals, and it is not known what level of exposure is required for teratogenicity in humans [see Clinical Pharmacology (12.3)].

Advise pregnant females of the potential risk to a fetus. Obtain a pregnancy test within 2 weeks prior to AVAGE Cream therapy. Initiate AVAGE Cream therapy during a menstrual period. Advise females of reproductive potential to use effective contraception during treatment with AVAGE Cream [see Dosage and Administration (2), Use in Specific Populations (8.3)].

5.2 Local Irritation and Hypersensitivity Reactions

Local tolerability reactions (including blistering and skin desquamation) and hypersensitivity adverse reactions (including urticaria) have been observed with topical tazarotene. Application of AVAGE Cream may cause excessive irritation in the skin of certain sensitive individuals. Some individuals may experience excessive pruritus, burning, skin redness, or peeling. If these adverse reactions occur, discontinue the medication until the integrity of the skin is restored, or reduce the dosing to an interval the patient can tolerate. Closely monitor the frequency of application by carefully observing the therapeutic response and skin tolerance.

Avoid concomitant use of topical medications and cosmetics that have a strong drying effect. It is also advisable to “rest” a patient’s skin until the effects of such preparations subside before use of AVAGE Cream is begun.

Avoid using AVAGE Cream on eczematous skin because such use may cause severe irritation.

Weather extremes, such as wind or cold, may be more irritating to patients using AVAGE Cream.

5.3 Photosensitivity and Risk of Sunburn

Because of heightened burning susceptibility, minimize exposure to ultraviolet rays (including sunlight and sun lamps) during the use of AVAGE Cream. Patients must be warned to use sunscreens and protective clothing when using AVAGE Cream. Advise patients with sunburn not to use AVAGE Cream until the sunburn is fully recovered.

Patients who may have considerable sun exposure because of their occupation and those patients with inherent sensitivity to sunlight should exercise particular caution when using AVAGE Cream.

Avoid using AVAGE Cream if the patient is also taking drugs known to be photosensitizers (e.g., thiazides, tetracyclines, fluoroquinolones, phenothiazines, sulfonamides) because of the increased possibility of augmented photosensitivity.

5.4 Lentigo Maligna

Some facial pigmented lesions are not lentigines, but rather lentigo maligna, a type of melanoma. Before application of AVAGE Cream, carefully assess facial pigmented lesions of concern by a qualified physician (e.g., dermatologist) to exclude a diagnosis of lentigo maligna.


The following serious adverse reactions are discussed in more detail in other sections of the labeling:

  • Embryofetal toxicity [see Warnings and Precautions (5.1)]
  • Photosensitivity and Risk of Sunburn [see Warnings and Precautions (5.3)]

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2020. All Rights Reserved.